New pill takes on Hard-to-Treat blood cancers
NCT ID NCT07424833
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage trial tests a daily pill called APG-3288 in 180 adults with blood cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look for any signs that the drug is shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APG-3288
- What this could lead to
- If this trial succeeds, it could point toward a new treatment option for people with blood cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 study, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. It will take years before any potential treatment is available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Mayo Clinic
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
-
START Los Angele
RECRUITINGLos Angeles, California, 90025, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START New Jersey
RECRUITINGEast Brunswick, New Jersey, 08816, United States
-
The University of TX MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.